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23.4%, ranging from 4% to 100%. Complete revascularization
(SRI¼100%) was achieved in 64.3% of patients, SRI¼ 50-99% in 472
patients (25.5%), and SRI <50% in 189 patients (10.2%). The 2-year
rates of mortality (0.4%, 1.9%, and 2.7%, p¼0.001) and MACE (6.0%,
11.4%, and 10.1%, p<0.001) were higher in patients with lower SRI.
By ROC analysis, an SRI cut-off of 85% showed the best prognostic
accuracy for 2-year mortality. A SRI of 85% had similar low all-
cause death and cardiac death rates when compared to complete
(SRI¼100%) revascularization (Figure). By multivariable analysis,
SRI was a strong predictor of 2-year mortality (HR: 4.20, 95% CI:
1.46-12.08, p¼0.008) and 2-year MACE (HR: 1.59, 95% CI: 1.14-2.23,
p¼0.007).
CONCLUSIONS In patients with complex CAD undergoing EES-PCI,
the SRI was identiﬁed as a strong predictor of 2-years mortality and
MACE. Given its correlation with mortality, the SRI may be useful in
assessing the degree of revascularization after PCI, with SRI 85% as a
reasonable goal.
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BACKGROUND Recurrent chest pain after successful percutaneous
coronary intervention (PCI) is the main trigger of repeat assessment
and resource utilization. PCI of bifurcated target lesions are often
complex and bear a higher risk of adverse events and chest pain.
METHODS To compare 2-year clinical outcome and patient-reported
chest pain of patients with bifurcated vs. non-bifurcated lesions, we
assessed data of the DUTCH PEERS randomized trial (clinicaltrials.gov
NCT01331707), in which 1,811 all-comers were treated with zotar-
olimus-eluting Resolute Integrity (Medtronic) or everolimus-eluting
Promus Element (Boston Scientiﬁc) stents. Among 465 patients with
bifurcated lesions, we also compared the outcome of patients withtrue bifurcation lesions (i.e. lesions with side-branch involvement) vs.
non-true bifurcation lesion. The primary endpoint target lesion failure
(TLF) is a composite of cardiac death, target vessel myocardial
infarction (MI), and target lesion revascularization.
RESULTS Clinical follow-up was available in 1,810 patients (99.9%).
TLF was similar in patients with and without bifurcated lesions
(8.2% vs. 6.9%, p¼0.37). Target vessel MI was more common in pa-
tients with bifurcated lesions, however, after multivariate analysis
with use of a propensity score, this relation turned out to be not
statistically signiﬁcant (HR 1.40, 95%CI 0.71-2.76, p¼0.34). There was
no difference in TLF between patients treated for true vs. non-true
bifurcation lesions (8.9% vs. 7.8%, p¼0.70). At 1 and 2-year follow-
up, 88.0% and 88.1% of patients with bifurcated lesions and 87.7%
and 87.8% of patients with non-bifurcated lesions were free from
clinically relevant chest pain (p¼0.89 and 0.87, respectively). Be-
tween patients with true vs. non-true bifurcation lesions, no differ-
ence in patient-reported chest pain at 1 and 2-year follow-up was
observed (86.5% vs. 88.5%, p¼0.54, and 90.2% vs. 86.7%, p¼0.30,
respectively).
CONCLUSIONS The rates of chest pain were low and similar in pa-
tients with bifurcated versus non-bifurcated target lesions, who
showed favorable clinical outcomes at 1 and 2-year follow-up after
treatment with contemporary ﬂexible drug-eluting stents.
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BACKGROUND High-risk percutaneous coronary intervention (PCI)
supported by percutaneous left ventricular assist devices offers a
treatment option for patients with severe symptoms, complex and
extensive coronary artery disease (CAD), and multiple comorbidities.
The extrapolation from clinical trial to real-world practice has
inherent uncertainties. We compared the characteristics, procedures,
and outcomes of high-risk PCI supported by a microaxial pump
(Impella 2.5) in a multicenter registry versus the randomized PRO-
TECT II trial (NCT00562016).
METHODS The USpella registry is an observational multicenter
voluntary registry of lmpella technology in 47 sites in the United
States and 2 sites in Canada. A total of 637 patients undergoing high-
risk PCI supported by Impella 2.5 between 6/2007 and 9/2013 were
included in this analysis. Of them, 339 patients would have met
enrollment criteria for the PROTECT II trial. Baseline variables, pro-
cedural characteristics, and in-hospital outcomes of these registry
patients were compared with 216 patients treated in the Impella arm
of the PROTECT II trial. All events were centrally adjudicated by an
independent clinical events committee.
RESULTS Compared to the clinical trial, registry patients were older
(7011.5 vs. 67.511.0 years), more likely to have chronic kidney
disease (30% vs. 22.7%), prior myocardial infarction (69.3% vs.
56.5%), prior by-pass surgery (39.4% vs. 30.2%), and had similar
prevalence of diabetes, peripheral vascular disease, and prior stroke.
Registry patients had more extensive CAD (2.2 vs. 1.8 diseased ves-
sels), and had a similar STS predicted risk of mortality (6.06.0 vs.
5.86.0, p¼0.64). Left ventricular ejection fraction was 23.46.3%
and 21.67.7%, in the registry and clinical trial, respectively
(p¼0.004). Use of rotational atherectomy was similar (16.4% vs.
14.8%, p¼0.63), but the number of passes per lesion was signiﬁcantly
